LCGC Asia Pacific
UltraPerformance LC (UPLC) has been widely accepted by chromatographers because of improvements over HPLC in the sensitivity, resolution and speed of separations. As scientists begin to use this technology for impurity and metabolite profiling, they will need to transfer the methods to preparative LC to isolate and purify their compounds for further research. Therefore, it is necessary to systematically transfer UPLC assays not only to HPLC, but, more importantly, to preparative chromatography. In this application, we provide information on how to scale a UPLC impurity/degradant separation to a preparative LC separation.
UltraPerformance LC (UPLC) has been widely accepted by chromatographers because of improvements over HPLC in the sensitivity, resolution and speed of separations. As scientists begin to use this technology for impurity and metabolite profiling, they will need to transfer the methods to preparative LC to isolate and purify their compounds for further research. Therefore, it is necessary to systematically transfer UPLC assays not only to HPLC, but, more importantly, to preparative chromatography. In this application, we provide information on how to scale a UPLC impurity/degradant separation to a preparative LC separation.
The UPLC separation of the ranitidine degradation sample is shown in Figure 1(a). Ranitidine is clearly resolved from all other compounds in the mixture and the entire cycle time is only 10 min. The boxed peak is the analyte that needs to be collected for identification. The separation is first directly scaled to a 19 × 150 mm XBridge Prep OBD C18 column. This column dimension was chosen to maintain the same column length (L) to particle size ratio (dp) as in the UPLC separation to ensure constant plate count and, therefore, maintain resolution. The XBridge chemistry is built on the same second generation bridged ethyl hybrid (BEH) particle as the ACQUITY UPLC BEH chemistry; therefore, the same selectivity is maintained as we scale separations. As shown in Figure 1(b), to maintain the selectivity and resolution, the overall cycle time needed to be increased to over 88 min. This long cycle time is not very practical for most separation scientists.
Therefore, modification of the gradient profile is necessary to help reduce the cycle time. We started the gradient at a higher % organic, maintained the same gradient slope to separate the component of interest from ranitidine, and quickly ramped to 90% organic to wash all other compounds off the column. The total cycle time has been reduced by 80%. Results are shown in Figure 1(c).
Figure 1
UPLC separations are seamlessly transferred to preparative LC by using traditional scaling principles. Further optimization is easily achieved by simple modification of the gradient profile. The use of the XBridge Prep OBD columns, built on the same base particle as ACQUITY UPLC BEH columns, facilitates this transfer.
© 2007 Waters Corporation. Waters, UPLC, ACQUITY UPLC, UltraPerformance LC, XBridge, OBD, AutoPurification, and The Science of What's Possible are trademarks of Waters Corporation.
Fang Xia, Jie Y. Cavanaugh, Diane M. Diehl, Thomas E. Wheat and Jeffrey R. Mazzeo, Waters Corporation, Milford, Massachusetts, USA.
Waters Corporation
34 Maple Street, Milford, Massachusetts 01757, USA
tel. +1 508 478 2000 fax +1 508 478 1990
Website: www.waters.com
Using LC-MS/MS Analysis for PFAS Detection in Biological Samples and Serum
November 1st 2024Per- and polyfluoroalkyl substances (PFAS) are exceptionally versatile chemicals and have seemingly endless applications. Due to their persistent nature; prevalence in blood, food and environment; and emerging toxicity, there is a significant concern for their presence in the human body. Analysis is especially complicated due to background contamination in laboratory supplies and system. This paper will discuss sample preparation and LC-MS/MS analysis of an expanded panel of PFAS compounds in serum.
Robust Oligonucleotide Molecular Weight Confirmation via LC/MS
October 31st 2024Oligonucleotides—therapeutic agents for difficult-to-treat diseases—rely on precise molecular weight confirmation to ensure quality during development. Experts from Agilent Technologies explore the challenges of liquid chromatography-mass spectrometry (LC/MS) analysis in oligonucleotide synthesis, as well as strategies for accurate deconvolution, method development, and optimal equipment selection.